A multicentric clinical study was conducted on representative sera from 1,738 European and U.S. subjects for the evaluation of new anti-hepatitis A virus enzyme immunoassays from Bio-Rad Laboratories. Comparison with reference DiaSorin S.p.A. tests confirmed the good performance of Bio-Rad assays (99.85% and 99.47% overall agreement in detecting total antibodies and IgM, respectively).The etiological agent of hepatitis A is a nonenveloped, positive-stranded RNA virus that is typically transmitted via the fecal-oral route (4).Hepatitis A virus (HAV) infection is still the most common cause of acute viral hepatitis worldwide and remains a serious health problem not only in the developing world, but also in industrialized countries (6, 10). It can lead to a multiplicity of clinical features, ranging from asymptomatic infection to fulminant fatal disease (16).Over the last decades, improvement in the living conditions of several world populations has prevented young people from acquiring asymptomatic infection (which provides lifelong protection), leaving them susceptible to hepatitis A infection (2, 4). With regard to adults, certain categories of people, such as men who have sexual intercourse with men, both injection and noninjection drug users, and travelers returning from developing countries, are exposed to a higher risk of infection and therefore are subjected to cyclic outbreaks of hepatitis A (1,3,8,11,12,15,17,18). It is also worth mentioning that HAVinfected persons with chronic liver disease are likely to develop fulminant hepatitis A (14, 16). This global scenario of hepatitis A epidemiology calls for an increase in research to be carried out in the coming years and for measures to be taken to control and prevent the spread of this infectious disease. In particular, vaccination against hepatitis A is recommended for all the aforementioned high-risk categories of people and represents an important tool in the prevention of virus spread and epidemic outbreaks (5).Laboratory diagnosis of hepatitis A is based mainly on the detection of antibodies associated with acute and past infection (IgM and IgG, respectively); complementary tests can be used in some cases for the diagnosis of recent infection (9, 13). In prevaccination programs, however, the detection of total anti-HAV antibodies is also critical for establishing whether individuals have acquired immunity and for identifying those susceptible to HAV infection.This study aimed to evaluate the performance of two novel anti-HAV enzyme immunoassays (EIA) developed by Bio-Rad Laboratories (the Monolisa anti-HAV IgM EIA and the Monolisa anti-HAV EIA) and to compare their results to those obtained using the FDA-approved ETI-AB-HAV-IgMK Plus and ETI-AB-HAVK Plus assays from DiaSorin S.p.A. The tests were performed and the results interpreted according to the manufacturers' instructions. Relative sensitivity and specificity, as well as agreement between the Bio-Rad and DiaSorin assay results, were calculated, with unresolved equivocal (concordant and discordant...